NxStage Medical Inc. (NASDAQ:NXTM) President Joseph E. Turk, Jr. sold 1,000 shares of the stock in a transaction on Thursday, November 17th. The stock was sold at an average price of $25.97, for a total transaction of $25,970.00. Following the completion of the sale, the president now directly owns 79,780 shares of the company’s stock, valued at approximately $2,071,886.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

NxStage Medical Inc. (NASDAQ:NXTM) traded down 0.72% on Monday, reaching $26.11. 120,306 shares of the company’s stock were exchanged. The firm has a 50 day moving average of $24.25 and a 200 day moving average of $22.22. The stock’s market capitalization is $1.69 billion. NxStage Medical Inc. has a 12 month low of $13.49 and a 12 month high of $26.83.

Insider Buying and Selling by Quarter for NxStage Medical (NASDAQ:NXTM)

Several research analysts have recently weighed in on NXTM shares. Northland Securities set a $25.00 target price on shares of NxStage Medical and gave the company a “buy” rating in a research note on Thursday, September 15th. Zacks Investment Research upgraded shares of NxStage Medical from a “hold” rating to a “strong-buy” rating and set a $24.00 target price for the company in a research note on Thursday, November 3rd. Jefferies Group upped their target price on shares of NxStage Medical from $24.00 to $27.00 and gave the company a “buy” rating in a research note on Friday, August 5th. Canaccord Genuity restated a “buy” rating and issued a $28.00 target price on shares of NxStage Medical in a research note on Thursday, November 3rd. Finally, BTIG Research restated a “buy” rating and issued a $29.00 target price on shares of NxStage Medical in a research note on Sunday, August 7th. One equities research analyst has rated the stock with a sell rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. NxStage Medical presently has a consensus rating of “Buy” and an average target price of $25.67.

Hedge funds have recently bought and sold shares of the company. Acrospire Investment Management LLC boosted its stake in NxStage Medical by 1,459.3% in the second quarter. Acrospire Investment Management LLC now owns 4,678 shares of the medical device company’s stock valued at $101,000 after buying an additional 4,378 shares in the last quarter. Pacad Investment Ltd. bought a new stake in NxStage Medical during the second quarter valued at approximately $111,000. BNP Paribas Arbitrage SA boosted its stake in NxStage Medical by 57.5% in the second quarter. BNP Paribas Arbitrage SA now owns 5,548 shares of the medical device company’s stock valued at $120,000 after buying an additional 2,026 shares in the last quarter. BlackRock Inc. boosted its stake in NxStage Medical by 50.6% in the second quarter. BlackRock Inc. now owns 6,299 shares of the medical device company’s stock valued at $136,000 after buying an additional 2,116 shares in the last quarter. Finally, Cutler Group LP boosted its stake in NxStage Medical by 28.3% in the second quarter. Cutler Group LP now owns 7,168 shares of the medical device company’s stock valued at $155,000 after buying an additional 1,583 shares in the last quarter. Institutional investors and hedge funds own 98.86% of the company’s stock.

NxStage Medical Company Profile

NxStage Medical, Inc is a medical technology company. The Company is engaged in the development, manufacturing and marketing of products and services for patients suffering from chronic or acute kidney failure. The Company operates through three segments: System One, In-Center and Services. It offers its products and services to various markets, such as home, critical care and in-center.

5 Day Chart for NASDAQ:NXTM

Receive News & Stock Ratings for NxStage Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical Inc. and related stocks with our FREE daily email newsletter.